Peptide LibraryDipeptide Diaminobutyroyl Benzylamide Diacetate
Also known as: Waglerin-1 mimetic, Tripeptide-3
Dipeptide Diaminobutyroyl Benzylamide Diacetate (also called Waglerin-1 mimetic or Tripeptide-3) is a cosmetic nicotinic antagonist mimetic. This dipeptide is a synthetic mimetic of waglerin-1, a component of temple viper venom that antagonises the muscle-type nicotinic acetylcholine receptor. In vitro it shows reversible antagonist-like activity at the postsynaptic receptor of the neuromuscular junction, reducing the depolarisation that initiates muscle contraction.
For research use only.
Key Facts
- CAS
- 823202-99-9
- Molecular Weight (MW)
- —
- Half-life
- Topical; systemic PK not established
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Muscle nAChR (model systems)
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 2
- Listed offers
- 2
- Price per mg
- $0.130/mg
Research summary
Waglerin-1–inspired tripeptide used in cosmetics to reduce expression-line appearance. Topical cosmetic active, not an FDA drug.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studies1 reviewed source
- Lab & animal studies1 reviewed source
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Dipeptide Diaminobutyroyl Benzylamide Diacetate profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Dipeptide Diaminobutyroyl Benzylamide Diacetate dosage: no established human dose
Dipeptide diaminobutyroyl benzylamide diacetate (Syn-Ake) has no established human dosage. It is a cosmetic ingredient, and no controlled human study of it could be found. Its human data come from a serum that combined it with acetyl hexapeptide-8 and other actives; other work is laboratory and computer modelling.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Syn-Ake is a small synthetic peptide used in anti-wrinkle cosmetics. Its evidence is laboratory and modelling work plus studies of a multi-ingredient serum. No controlled human study of it alone and no study by injection could be found, so no strength, amount, route or interval is established.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Topical (cosmetic use); not established for injection |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Ex vivo and clinical studies — multi-ingredient serum (Zhu et al., 2026)Clinical trial · Clinical studies of a multi-ingredient product | Two clinical studies: 50 participants (static wrinkles) and 42 participants (dynamic wrinkles) | Not stated in the indexed abstract; the serum combined acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria extract | Topical (face) | — | 12 weeks | Clinical scores for static wrinkles improved 35%–69% and dynamic wrinkles 10%–13% (all p < 0.001); a control group is not stated in the abstract | Zhu M et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. Int J Cosmet Sci. 2026. |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Laboratory and modelling study (Gok et al., 2024)Preclinical · In silico and in vitro study | Computer docking models and cell and bacterial tests | Not stated in the indexed abstract | In vitro | — | — | Predicted binding to MMPs and SIRT1, concentration-dependent antioxidant activity, and safety in cytotoxicity and Ames tests | Gok B et al. Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests. J Biomol Struct Dyn. 2024. |
Where sources disagree
- A percentage or ppm in a cream is a formulation strength, not a dose, and cannot be converted into an amount for injection.
- Results for a serum that also contains acetyl hexapeptide-8 and other actives cannot be credited to Syn-Ake alone.
Sequence & molecular data
| Molecular formula | C23H37N5O7 (salt forms vary) |
|---|---|
| Molecular weight | — |
| CAS number | 823202-99-9 |
| Half-life | Topical; systemic PK not established |
| Appearance | Clear solution or powder (cosmetic grade) |
| Formulation | Topical Cream |
| PubChem CID | 71465152 |
| FDA UNII | 38H206R00R |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This dipeptide is a synthetic mimetic of waglerin-1, a component of temple viper venom that antagonises the muscle-type nicotinic acetylcholine receptor. In vitro it shows reversible antagonist-like activity at the postsynaptic receptor of the neuromuscular junction, reducing the depolarisation that initiates muscle contraction. Applied topically the intent is to reduce the microcontractions of facial expression muscles that produce dynamic lines, giving a mechanism conceptually parallel to botulinum toxin but acting on the receptor rather than on vesicle fusion, and far weaker. Whether a topically applied dipeptide reaches the neuromuscular junction in meaningful concentration is the central unresolved question; evidence is largely supplier-derived.
Origin
Synthetic tripeptide analog of temple-viper waglerin-1.
Targets
Studies
- Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests
- Microemulsions and Nanoemulsions for Topical Delivery of Tripeptide-3: From Design of Experiment to Anti-Sebum Efficacy on Facial Skin
- Role of Peptides in Skeletal Muscle Wasting: A Scoping Review
- Antidiabetic Potential of a Trimeric Anthranilic Acid Peptide Isolated from Malbranchea flocciformis
Research statistics
2 PubMed publications · 100.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Dipeptide Diaminobutyroyl Benzylamide Diacetate is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | OTC / Supplement |
| WADA (sport) | Permitted |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Dipeptide Diaminobutyroyl Benzylamide Diacetate side effects
Dipeptide Diaminobutyroyl Benzylamide Diacetate has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Irritation
- Redness
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Dipeptide Diaminobutyroyl Benzylamide Diacetate: frequently asked questions
What is Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Waglerin-1–inspired tripeptide used in cosmetics to reduce expression-line appearance. Topical cosmetic active, not an FDA drug.
How does Dipeptide Diaminobutyroyl Benzylamide Diacetate work?
This dipeptide is a synthetic mimetic of waglerin-1, a component of temple viper venom that antagonises the muscle-type nicotinic acetylcholine receptor. In vitro it shows reversible antagonist-like activity at the postsynaptic receptor of the neuromuscular junction, reducing the depolarisation that initiates muscle contraction.
Is Dipeptide Diaminobutyroyl Benzylamide Diacetate FDA approved?
No. Dipeptide Diaminobutyroyl Benzylamide Diacetate is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Reported half-life for Dipeptide Diaminobutyroyl Benzylamide Diacetate is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Dipeptide Diaminobutyroyl Benzylamide Diacetate banned in sport?
Dipeptide Diaminobutyroyl Benzylamide Diacetate is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Compounds most often compared with Dipeptide Diaminobutyroyl Benzylamide Diacetate include Acetyl Hexapeptide-8, Acetyl Octapeptide-3, Acetyl Tetrapeptide-3 and AHK-Cu. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- PubChem SYN-AKEExternal reference
- Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests — J Biomol Struct Dyn, 2024External reference
- Microemulsions and Nanoemulsions for Topical Delivery of Tripeptide-3: From Design of Experiment to Anti-Sebum Efficacy on Facial Skin — Pharmaceutics, 2024External reference
- Role of Peptides in Skeletal Muscle Wasting: A Scoping Review — J Cachexia Sarcopenia Muscle, 2025External reference
- Antidiabetic Potential of a Trimeric Anthranilic Acid Peptide Isolated from Malbranchea flocciformis — Chem Biodivers, 2024External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This Dipeptide Diaminobutyroyl Benzylamide Diacetate profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Dipeptide Diaminobutyroyl Benzylamide Diacetate research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →